Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 lenvatinib + pembrolizumab versus standard chemotherapy in previously treated metastatic colorectal cancer
MOH_2021-02-02_009562Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab and lenvatinib in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Merck & Co. Started Jan 2021; status: active, not recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on MOH_2021-02-02_009562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-02-02_009562.